To access this element change to forms mode OFF
Grant Award View - GA52669
Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of...
GA ID:
GA52669
Agency:
Cancer Australia
Approval Date:
8-Apr-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
1-Jun-2019 to 31-May-2022
Value (AUD):
$361,023.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
Targeting multidrug resistance protein 1 (MDR1) enhances the efficacy of Smac-mimetic-based therapy in Acute Myeloid Leukaemia.
Purpose:
Acute Myeloid Leukaemia (AML) is an aggressive blood cancer, and the second most common form of leukaemia in children. Fewer than 30% of AML patients can be cured with current therapies. This project will test a novel combination therapy, the Smac-mimetic drug birinapant plus multidrug resistance inhibitors (MDR1i), for the treatment of AML. The research will determine how this therapy can be effectively used to increase the chances of cure, with reduced side effects for the patient’s benefit.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Melbourne
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA